These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33009242)

  • 1. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
    Chen JY; Wang JJ; Lee HC; Chi CW; Lee CH; Hsu YC
    J Chin Med Assoc; 2020 Oct; 83(10):923-930. PubMed ID: 33009242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
    Burrage PS; Schmucker AC; Ren Y; Sporn MB; Brinckerhoff CE
    Arthritis Res Ther; 2008; 10(6):R139. PubMed ID: 19046432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
    Kotani H; Tanabe H; Mizukami H; Amagaya S; Inoue M
    Biol Pharm Bull; 2012; 35(1):1-9. PubMed ID: 22223330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
    Park JW; Zarnegar R; Kanauchi H; Wong MG; Hyun WC; Ginzinger DG; Lobo M; Cotter P; Duh QY; Clark OH
    Thyroid; 2005 Mar; 15(3):222-31. PubMed ID: 15785241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.
    Klopper JP; Hays WR; Sharma V; Baumbusch MA; Hershman JM; Haugen BR
    Mol Cancer Ther; 2004 Aug; 3(8):1011-20. PubMed ID: 15299084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARγ/ NF-κB signaling pathway in C6 glioma cells.
    Hacioglu C; Kar F; Kacar S; Sahinturk V; Kanbak G
    Med Oncol; 2021 Feb; 38(3):31. PubMed ID: 33599853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
    Klopper JP; Sharma V; Berenz A; Hays WR; Loi M; Pugazhenthi U; Said S; Haugen BR
    Mol Cancer; 2009 Mar; 8():16. PubMed ID: 19267912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal cells.
    Yanik SC; Baker AH; Mann KK; Schlezinger JJ
    Toxicol Sci; 2011 Aug; 122(2):476-88. PubMed ID: 21622945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.
    Chu R; van Hasselt A; Vlantis AC; Ng EK; Liu SY; Fan MD; Ng SK; Chan AB; Liu Z; Li XY; Chen GG
    Cancer; 2014 Jan; 120(1):142-53. PubMed ID: 24114184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of adipogenesis through retinoid X receptor and/or peroxisome proliferator-activated receptor by designed lignans based on natural products in 3T3-L1 cells.
    Nakashima KI; Okamura M; Matsumoto I; Kameda N; Tsuboi T; Yamaguchi E; Itoh A; Inoue M
    J Nat Med; 2023 Mar; 77(2):315-326. PubMed ID: 36607539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.
    Zuo Y; Huang L; Enkhjargal B; Xu W; Umut O; Travis ZD; Zhang G; Tang J; Liu F; Zhang JH
    J Neuroinflammation; 2019 Feb; 16(1):47. PubMed ID: 30791908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
    Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro.
    Liu Y; Zhu ZA; Zhang SN; Mou J; Liu L; Cui T; Pei DS
    Tumour Biol; 2013 Aug; 34(4):2409-18. PubMed ID: 23605322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
    Cesario RM; Stone J; Yen WC; Bissonnette RP; Lamph WW
    Cancer Lett; 2006 Aug; 240(2):225-33. PubMed ID: 16271436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
    D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
    J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
    Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
    J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoid X Receptor Activation During Adipogenesis of Female Mesenchymal Stem Cells Programs a Dysfunctional Adipocyte.
    Shoucri BM; Hung VT; Chamorro-García R; Shioda T; Blumberg B
    Endocrinology; 2018 Aug; 159(8):2863-2883. PubMed ID: 29860300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
    Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
    J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.